
Keywords: prostatic neoplasms; prostate-specific antigen; androgen antagonists; delayed-action preparations; calcium sulfate; 2D; 2-dimensional; 2-HOF; 2-hydroxyflutamide; ADC; apparent diffusion coefficient; Cho; choline; Cit; citrate; Cr; creatine; DWI; diffusion